Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation

Tadashi Ohara, Tetsuo Morishita, Hidekazu Suzuki, Tatsuhiro Masaoka, Toshihiro Nishizawa, Toshifumi Hibi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: It has previously been reported that human-β defensin 2 (hBD2) has a physiological role as a proinflammatory mediator in gastric mucosal inflammation as well as an antimicrobial peptide for Helicobacter pylori (Hp). The present study was conducted to evaluate the possibility of hBD2 as a molecular marker of gastric mucosal inflammation. Methodology: The subjects were 40 A1 to S2 gastric ulcer patients, with or without Hp infection. Biopsy specimens of the mucosa were obtained endoscopically before and after the administration of lansoprazole (LPZ) (15mg/day) or famotidine (FAM) (40mg/day or 20mg/day), consecutively, and each set of samples was divided into two groups; one group was subjected to RT-PCR to assess the expression of hBD2, and the other was subjected to immunohistochemical analysis for evaluating the expression of CD68. Results: The expression of hBD2 was observed through the stage of gastric ulcer, from A1 to S1, regardless of the presence or absence of Hp infection, both before and after LPZ or FAM administration, and its intensity of expression decreasing as the number of CD68-positive cells decreased. The number of CD68-positive cells deceased as the severity of the ulcer increased from stage A1 to S2, regardless of the presence/absence of Hp infection. CD68-positive cells could hardly be observed in stage S2 gastric ulcers, in which hBD2 expression was also only scarcely noted. Conclusions: These results suggested the possibility that hBD2 may be a molecular marker of gastric mucosal inflammation, irrespective of the presence/absence of Hp infection.

Original languageEnglish
Pages (from-to)1320-1324
Number of pages5
JournalHepato-Gastroenterology
Volume52
Issue number65
Publication statusPublished - 2005 Sep

Fingerprint

Defensins
Helicobacter pylori
Helicobacter Infections
Stomach
Inflammation
Stomach Ulcer
Famotidine
Lansoprazole
Ulcer
Mucous Membrane
Biopsy
Polymerase Chain Reaction
Peptides

Keywords

  • Antimicrobial peptide
  • Human-β defensin 2 (hBD2)
  • Molecular marker of gastric mucosal inflammation
  • Proinflammatory mediator

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation. / Ohara, Tadashi; Morishita, Tetsuo; Suzuki, Hidekazu; Masaoka, Tatsuhiro; Nishizawa, Toshihiro; Hibi, Toshifumi.

In: Hepato-Gastroenterology, Vol. 52, No. 65, 09.2005, p. 1320-1324.

Research output: Contribution to journalArticle

Ohara, T, Morishita, T, Suzuki, H, Masaoka, T, Nishizawa, T & Hibi, T 2005, 'Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation', Hepato-Gastroenterology, vol. 52, no. 65, pp. 1320-1324.
Ohara, Tadashi ; Morishita, Tetsuo ; Suzuki, Hidekazu ; Masaoka, Tatsuhiro ; Nishizawa, Toshihiro ; Hibi, Toshifumi. / Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation. In: Hepato-Gastroenterology. 2005 ; Vol. 52, No. 65. pp. 1320-1324.
@article{39c9eb3bc1e84db0b14fab92d446fd64,
title = "Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation",
abstract = "Background/Aims: It has previously been reported that human-β defensin 2 (hBD2) has a physiological role as a proinflammatory mediator in gastric mucosal inflammation as well as an antimicrobial peptide for Helicobacter pylori (Hp). The present study was conducted to evaluate the possibility of hBD2 as a molecular marker of gastric mucosal inflammation. Methodology: The subjects were 40 A1 to S2 gastric ulcer patients, with or without Hp infection. Biopsy specimens of the mucosa were obtained endoscopically before and after the administration of lansoprazole (LPZ) (15mg/day) or famotidine (FAM) (40mg/day or 20mg/day), consecutively, and each set of samples was divided into two groups; one group was subjected to RT-PCR to assess the expression of hBD2, and the other was subjected to immunohistochemical analysis for evaluating the expression of CD68. Results: The expression of hBD2 was observed through the stage of gastric ulcer, from A1 to S1, regardless of the presence or absence of Hp infection, both before and after LPZ or FAM administration, and its intensity of expression decreasing as the number of CD68-positive cells decreased. The number of CD68-positive cells deceased as the severity of the ulcer increased from stage A1 to S2, regardless of the presence/absence of Hp infection. CD68-positive cells could hardly be observed in stage S2 gastric ulcers, in which hBD2 expression was also only scarcely noted. Conclusions: These results suggested the possibility that hBD2 may be a molecular marker of gastric mucosal inflammation, irrespective of the presence/absence of Hp infection.",
keywords = "Antimicrobial peptide, Human-β defensin 2 (hBD2), Molecular marker of gastric mucosal inflammation, Proinflammatory mediator",
author = "Tadashi Ohara and Tetsuo Morishita and Hidekazu Suzuki and Tatsuhiro Masaoka and Toshihiro Nishizawa and Toshifumi Hibi",
year = "2005",
month = "9",
language = "English",
volume = "52",
pages = "1320--1324",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "65",

}

TY - JOUR

T1 - Investigation of the possibility of human-β defensin 2 (hBD2) as a molecular marker of gastric mucosal inflammation

AU - Ohara, Tadashi

AU - Morishita, Tetsuo

AU - Suzuki, Hidekazu

AU - Masaoka, Tatsuhiro

AU - Nishizawa, Toshihiro

AU - Hibi, Toshifumi

PY - 2005/9

Y1 - 2005/9

N2 - Background/Aims: It has previously been reported that human-β defensin 2 (hBD2) has a physiological role as a proinflammatory mediator in gastric mucosal inflammation as well as an antimicrobial peptide for Helicobacter pylori (Hp). The present study was conducted to evaluate the possibility of hBD2 as a molecular marker of gastric mucosal inflammation. Methodology: The subjects were 40 A1 to S2 gastric ulcer patients, with or without Hp infection. Biopsy specimens of the mucosa were obtained endoscopically before and after the administration of lansoprazole (LPZ) (15mg/day) or famotidine (FAM) (40mg/day or 20mg/day), consecutively, and each set of samples was divided into two groups; one group was subjected to RT-PCR to assess the expression of hBD2, and the other was subjected to immunohistochemical analysis for evaluating the expression of CD68. Results: The expression of hBD2 was observed through the stage of gastric ulcer, from A1 to S1, regardless of the presence or absence of Hp infection, both before and after LPZ or FAM administration, and its intensity of expression decreasing as the number of CD68-positive cells decreased. The number of CD68-positive cells deceased as the severity of the ulcer increased from stage A1 to S2, regardless of the presence/absence of Hp infection. CD68-positive cells could hardly be observed in stage S2 gastric ulcers, in which hBD2 expression was also only scarcely noted. Conclusions: These results suggested the possibility that hBD2 may be a molecular marker of gastric mucosal inflammation, irrespective of the presence/absence of Hp infection.

AB - Background/Aims: It has previously been reported that human-β defensin 2 (hBD2) has a physiological role as a proinflammatory mediator in gastric mucosal inflammation as well as an antimicrobial peptide for Helicobacter pylori (Hp). The present study was conducted to evaluate the possibility of hBD2 as a molecular marker of gastric mucosal inflammation. Methodology: The subjects were 40 A1 to S2 gastric ulcer patients, with or without Hp infection. Biopsy specimens of the mucosa were obtained endoscopically before and after the administration of lansoprazole (LPZ) (15mg/day) or famotidine (FAM) (40mg/day or 20mg/day), consecutively, and each set of samples was divided into two groups; one group was subjected to RT-PCR to assess the expression of hBD2, and the other was subjected to immunohistochemical analysis for evaluating the expression of CD68. Results: The expression of hBD2 was observed through the stage of gastric ulcer, from A1 to S1, regardless of the presence or absence of Hp infection, both before and after LPZ or FAM administration, and its intensity of expression decreasing as the number of CD68-positive cells decreased. The number of CD68-positive cells deceased as the severity of the ulcer increased from stage A1 to S2, regardless of the presence/absence of Hp infection. CD68-positive cells could hardly be observed in stage S2 gastric ulcers, in which hBD2 expression was also only scarcely noted. Conclusions: These results suggested the possibility that hBD2 may be a molecular marker of gastric mucosal inflammation, irrespective of the presence/absence of Hp infection.

KW - Antimicrobial peptide

KW - Human-β defensin 2 (hBD2)

KW - Molecular marker of gastric mucosal inflammation

KW - Proinflammatory mediator

UR - http://www.scopus.com/inward/record.url?scp=25844494436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844494436&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 1320

EP - 1324

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 65

ER -